Method for preparing (R)-N-acetyl-alpha-arylethylamine derivative through photoenzyme catalysis asymmetric reduction

Through the biocatalytic system excitated by blue light LED, the asymmetric reduction of enamide is performed using olefin reductase and cofactor circulation system under normal temperature and pressure, solving the cost and safety problems of precious metal catalysts in the prior art, achieving high efficiency , synthesis of green chiral amines.

CN118995869APending Publication Date: 2024-11-22NANJING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310574982.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing asymmetric synthesis methods of chiral amines mainly rely on precious metal catalysts and complex chiral phosphine ligands, and there are problems of high cost, heavy metal residues and insufficient process safety.

Method used

The cofactor FMNH- of olefin reductase was excited by blue light LED, and asymmetric reduction of enamide was performed under normal temperature and pressure through a biocatalytic system, and cofactors such as olefinic reductase, sodium flavin single nucleotide and glucose dehydrogenase were used. Circulation system to achieve efficient preparation of (R)-N-acetyl-α-arylethylamine derivatives.

Benefits of technology

Achieving asymmetric reduction reaction of high yield and enantioselectivity of biocatalytic asymmetric acrylamide, providing a green and efficient biosynthesis path, reducing production costs and avoiding heavy metal residues, suitable for a variety of heterocyclic compounds compatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995869A_ABST
    Figure CN118995869A_ABST
Patent Text Reader

Abstract

The invention discloses a method for preparing a (R)-N-acetyl-alpha-arylethylamine derivative through photoenzyme catalysis asymmetric reduction. The method comprises the following steps: irradiating a substrate acrylamide in a buffer salt solution containing a cosolvent by using an alkene reductase as a biocatalyst in the presence of an alkene reductase cofactor and a cofactor circulating system in a nitrogen atmosphere by using an LED (Light Emitting Diode) light source, and stirring to react. According to the method disclosed by the invention, a high-yield and enantioselective biocatalytic asymmetric reduction reaction of alkenyl amide is realized, a green and efficient new biosynthesis path is provided for asymmetric synthesis of chiral amine, and the method has a potential important application prospect in the pharmaceutical industry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of asymmetric hydrogenation preparation of ene amides, and in particular to a method for preparing (R)-N-acetyl-α-arylethylamine derivatives by photoenzyme-catalyzed asymmetric reduction. Background Art

[0002] Chiral amine structural skeletons exhibit unique physicochemical properties and biological activities and are important structural units in many drugs, natural products and bioactive molecules. Developing an efficient and green catalytic method for the asymmetric synthesis of chiral amines is an important challenge in the field of drug synthesis. In recent years, the use of light-excited enzymes or enzyme-substrate complexes has become an emerging strategy to obtain new enzyme catalytic functions. On the one hand, the introduction of photoactive cofactors such as flavin mononucleotide (FMN) and nicotinamide adenine dinucleotide phosphate (NAD(P)H) or photocatalysts can bring new reactivity to the enzyme catalytic process; on the other hand, the protein skeleton of the enzyme can provide a better binding environment for the substrate through directed evolution, thereby achieving high stereo and chemical selectivity and high reactivity.

[0003] Asymmetric hydrogenation of enamides is an efficient way to obtain chiral amines with high atom economy. In 1972, Kagan's team reported the first asymmetric hydrogenation method of N-acetylenamides. By using rhodium complexes and the bisphosphine ligand Diop, a new method was developed to prepare enantiomer-enriched acetamides. Subsequently, the Knowles team, the Noyori team and the Burk team introduced several chiral bisphosphine ligands, DIPAMP, BINAP and DuPhos, for rhodium-catalyzed asymmetric reduction of enamides. In the following decades, many rhodium catalysts containing chiral bisphosphine ligands or monophosphine ligands were developed, making the direct catalytic hydrogenation of enamide compounds one of the preferred methods for synthesizing amino acids and chiral amines with stereocenters at the α or β position of the nitrogen atom, and it has been widely used in the synthesis of drug molecules. Evano's team recently developed a total synthesis method for Conulothiazole A, which was carried out in 7 steps with a total yield of 30%. One of the key steps is to use rhodium catalyst and (S,S)-QuinoxP* chiral phosphine ligand catalytic system to achieve the construction of chiral amine structure.

[0004] At present, the more mature asymmetric synthesis methods of chiral amines are mainly achieved by using transition metals combined with chiral phosphine ligands, and performing asymmetric catalytic hydrogenation reactions or asymmetric reductive amination reactions in the presence of hydrogen. This type of chemical synthesis system usually requires the use of precious metal catalysts such as rhodium and iridium, complex chiral ligands, and high-pressure hydrogen, and faces problems such as high cost and heavy metal residues, and has certain shortcomings in production cost and process safety. Summary of the invention

[0005] In view of the deficiencies of the prior art, the present invention provides a method for preparing (R)-N-acetyl-α-arylethylamine derivatives by photoenzyme-catalyzed asymmetric reduction. The present invention uses a blue light LED to excite the cofactor FMNH- of the "ene" reductase, which can significantly improve the reducing ability of the enzyme and achieve the reduction of the electron-rich C=C bond of the ene amide. The method of the present invention achieves a high-yield and enantioselective biocatalytic ene amide asymmetric reduction reaction, provides a new green and efficient biosynthetic pathway for the asymmetric synthesis of chiral amines, and has potential important application prospects in the pharmaceutical industry.

[0006] The technical solution of the present invention is as follows:

[0007] A method for preparing (R)-N-acetyl-α-arylethylamine derivatives by photoenzyme-catalyzed asymmetric reduction, wherein the substrate enamide is irradiated with an LED light source in a buffered salt solution containing a cosolvent, an olefin reductase is used as a biocatalyst, and an olefin reductase cofactor and a cofactor circulation system are present in a nitrogen atmosphere, and the reaction is obtained by stirring. The general reaction formula is as follows:

[0008]

[0009] in:

[0010] Ar includes phenyl, C 1 -C 6 substituted phenyl, α-naphthyl, β-naphthyl or heterocyclic substituents;

[0011] R 1 Selected from acetyl, tert-butyloxycarbonyl, trifluoroacetyl, benzoyl;

[0012] R 2 is selected from a hydrogen atom, an alkyl group, and an allyl group;

[0013] R 3 is selected from a hydrogen atom or an alkyl group.

[0014] Furthermore, the phenyl substituent (i.e., C 1 -C 6 The substituted phenyl) is selected from a halogen atom, a methoxy group, a methylthio group, a methyl group, a tert-butyl group, a trifluoromethyl group, an ester group, and a cyano group.

[0015] Furthermore, the heterocyclic substituent is selected from common heterocyclic structures such as thiazole, thiophene, furan, benzofuran, benzothiophene, and pyridine.

[0016] Furthermore, the olefin reductase cofactor is flavin mononucleotide sodium (FMN-Na).

[0017] Furthermore, the cofactor circulation system includes glucose dehydrogenase (GDH) solution, oxidized nicotinamide purine dinucleotide phosphate (NADP + ) solution and D-glucose solution.

[0018] Furthermore, the olefin reductase includes one of OYE1, OYE1 mutant, OPR1, YersER, NostocER, and NCR; and the olefin reductase is obtained by expression in E.coli BL21 (DE3) and protein purification.

[0019] Furthermore, the olefin reductase OYE1 mutant is a mutant having at least one of the following mutations compared with SEQ ID No.1: F296G / F296A / F296L / Y196F / Y375F / F250A / F250L / F250G / N194A / F374A. That is, the phenylalanine at position 296 of SEQ ID No.1 is substituted with glycine, alanine or leucine; the tyrosine at position 196 is substituted with phenylalanine; the tyrosine at position 375 is substituted with phenylalanine; the phenylalanine at position 250 is substituted with alanine, leucine or glycine; the asparagine at position 194 is substituted with alanine; the phenylalanine at position 374 is substituted with alanine; the mutant is obtained by one or more of the above mutations.

[0020] Furthermore, the LED light source is a blue LED light source with a wavelength of 390-430 nm; the reaction time is 12-24 hours; the co-solvent includes dimethyl sulfoxide, isopropanol, acetonitrile or N,N-dimethylformamide; and the volume ratio of the co-solvent in the buffered saline solution is 1-10%.

[0021] Furthermore, the method specifically includes the following steps:

[0022] (1) Add buffer solution, olefin reductase, reductase cofactor, glucose dehydrogenase (GDH), oxidized nicotinamide purine dinucleotide phosphate (NADP) to the reaction vessel in sequence. + ), D-glucose to obtain a mixed solution, then add the substrate enamide to obtain a reaction solution, and react at room temperature under nitrogen atmosphere and LED light for 12-24h;

[0023] (2) After the reaction is completed, a saturated sodium carbonate solution and ethyl acetate are added to the reaction container in sequence for extraction to obtain a (R)-N-acetyl-α-arylethylamine derivative, and then the reaction yield is analyzed by gas chromatography (internal standard curve method), and the enantiomeric selectivity is analyzed by high performance liquid chromatography (chiral chromatography column).

[0024] Furthermore, in step (1), the buffer salt includes phosphate, tris(hydroxymethyl)aminomethane hydrochloride, 3-(N-morpholinyl)propanesulfonate, hydroxyethylpiperazine ethanesulfonate or tris(hydroxymethyl)methylglycine, and the concentration of the buffer salt solution is 25-200 mmol / L and the pH is 7.0-9.0.

[0025] Furthermore, in step (1), the amount of the olefin reductase relative to the substrate is 0.5-3 mol%; the olefin reductase cofactor is flavin mononucleotide sodium, and the amount of the olefin reductase cofactor relative to the substrate is 0-3 mol%.

[0026] Further, when the concentration of the olefin reductase cofactor is 0%, the reaction system still contains the olefin reductase itself to produce the olefin reductase cofactor;

[0027] Furthermore, when the amount of the olefin reductase cofactor solution relative to the substrate is 0.5-3%, the yield is significantly improved.

[0028] Furthermore, in step (1), in the reaction solution, the concentration of glucose dehydrogenase is 1-20 U / mL; the amount of oxidized nicotinamide purine dinucleotide phosphate relative to the substrate is 2-20 mol%; the equivalent of D-glucose is 2-10 equivalents; and in step (2), the volume ratio of the saturated sodium carbonate solution to ethyl acetate is 1:1-10.

[0029] The beneficial technical effects of the present invention are:

[0030] The present invention uses a green and sustainable enzyme catalyst to replace the traditional metal catalytic system, which can reduce costs, simplify the process, and eliminate the problems of heavy metal residues.

[0031] The reaction conditions of the present invention are mild and can be carried out at room temperature and pressure; the substrate of the present invention has a wide range of applications and is compatible with a variety of heterocyclic compounds; and products with complementary stereo configurations can be quickly obtained through directed evolution.

[0032] The present invention develops a mature biocatalytic method for preparing chiral amides, which can serve as an important supplement to traditional transition metal catalytic methods, realizes the green, sustainable and efficient synthesis of chiral amines, and has important significance in the pharmaceutical industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is the chiral HPLC chart of the racemic standard N-(1-phenylethyl)acetamide.

[0034] Figure 2 The chiral HPLC chart of the enantiomerically enriched product (R)-N-(1-phenylethyl)acetamide.

[0035] Figure 3 For the racemic standard N-(1-phenylethyl)acetamide 1 H-NMR spectrum.

[0036] Figure 4 For the racemic standard N-(1-phenylethyl)acetamide 13 C-NMR spectrum. DETAILED DESCRIPTION

[0037] The present invention will be described in detail below in conjunction with the embodiments.

[0038] The present invention combines photoredox catalysis with "ene" reductase catalysis to develop a new photoenzyme catalysis system to achieve asymmetric reduction of enamide.

[0039] The preparation route of the (R)-N-acetyl-α-arylethylamine derivatives of the present invention is as follows:

[0040]

[0041] in:

[0042] Ar includes phenyl, C 1 -C 6 substituted phenyl, α-naphthyl, β-naphthyl or heterocyclic substituents;

[0043] R 1 Including but not limited to acetyl, tert-butyloxycarbonyl, trifluoroacetyl, benzoyl;

[0044] R 2 Including but not limited to hydrogen atoms, alkyl groups, and allyl groups;

[0045] R 3 These include, but are not limited to, a hydrogen atom or an alkyl group.

[0046] The phenyl substituents include, but are not limited to, halogen atoms, methoxy, methylthio, methyl, tert-butyl, trifluoromethyl, ester, and cyano.

[0047] The heterocyclic substituents include, but are not limited to, common heterocyclic structures such as thiazole, thiophene, furan, benzofuran, benzothiophene, and pyridine.

[0048] The olefin reductase includes one of olefin reductase OYE1, OYE1 mutant, GluER, OPR1, YersER, NostocER, and NCR.

[0049] The olefin reductase OYE1 was obtained by transferring a purchased plasmid into competent Escherichia coli (commercial E. coli BL21 (DE3)), culturing in commercial TB medium for 4 hours, and then adding isopropyl-β-D-thiogalactoside to induce protein expression for 16 hours.

[0050] The olefin reductase mutant is constructed by point mutation method, and the specific preparation method is the same as above.

[0051] The amino acid sequence of OYE1 is shown in SEQ ID No. 1:

[0052] MSFVKDFKPQALGDTNLFKPIKIGNNELLHRAVIPPLTRMRALHPGNIPNRDWAVEYYTQRAQRPGTMIITEGAFISPQAGGYDNAPGVWSEEQMVEWTKIF NAIHEKKSFVWVQLWVLGWAAFPDNLARDGLRYDSASDNVFMDAEQEAKAKKANNPQHSLTKDEIKQYIKEYVQAAKNSIAAGADGVEIHSANGYLLNQFLD PHSNTRTDEYGGSIENRARFTLEVVDALVEAIGHEKVGLRLSPYGVFNSMSGGAETGIVAQYAYVAGELEKRAKAGKRLAFVHLVEPRVTNPFLTEGEGEYE GGSNDFVYSIWKGPVIRAGNFALHPEVVREEVKDKRTLIGYGRFFISNPDLVDRLEKGLPLNKYDRDTFYQMSAHGYIDYPTYEEALKLGWDKKLEHHHHHH.

[0053] Preferably, the olefin reductase mutant is one of OYE1-F296G, OYE1-F296G-Y196F or OYE1-F296G-Y375F.

[0054] (1) OYE1-F296G: In the amino acid sequence of OYE1 shown, phenylalanine at position 296 was substituted with glycine;

[0055] (2) OYE1-F296G-Y196F: In the amino acid sequence of OYE1, phenylalanine at position 296 was substituted with glycine, and tyrosine at position 196 was substituted with phenylalanine;

[0056] (3) OYE1-F296G-Y375F: In the amino acid sequence of OYE1, phenylalanine at position 296 was substituted with glycine, and tyrosine at position 375 was substituted with phenylalanine;

[0057] The amino acid sequence of GluER is shown in SEQ ID No.2:

[0058] MHHHHHHPTLFDPIDFGPIHAKNRIVMSPLTRGRADKEAVPTPIMAEYYA

[0059] QRASAGLIITEATGISREGLGWPFAPGIWSDAQVEAWKPIVAGVHAKGGKIVC

[0060] QLWHMGRMVHSSVTGTQPVSSSATTAPGEVHTYEGKKPFEQARAIDAADISR

[0061] ILNDYENAARNAIRAGFDGVQIHAANGYLIDEFLRNGTNHRTDEYGGVPENR

[0062] IRFLKEVTERVIAAIGADRTGVRLSPNGDTQGCIDSAPETVFVPAAKLLQDLGV

[0063] AWLELREPGPNGTFGKTDQPKLSPQIRKVFLRPLVLNQDYTFEAAQTALAEG

[0064] KADAIAFGRKFISNPDLPERFARGIALQPDDMKTWYSQGPEGYTDYPSATSGPN。

[0065] The amino acid sequence of OPR1 is shown in SEQ ID No.3:

[0066] MENKVVEEKQVDKIPLMSPCKMGKFELCHRVVLAPLTRQRSYGYIPQPH

[0067] AILHYSQRSTNGGLLIGEATVISETGIGYKDVPGIWTKEQVEAWKPIVDAVHA

[0068] KGGIFFCQIWHVGRVSNKDFQPNGEDPISCTDRGLTPQIRSNGIDIAHFTRPRRL

[0069] TTDEIPQIVNEFRVAARNAIEAGFDGVEIHGAHGYLIDQFMKDQVNDRSDKY

[0070] GGSLENRCRFALEIVEAVANEIGSDRVGIRISPFAHYNEAGDTNPTALGLYMVE

[0071] SLNKYDLAYCHVVEPRMKTAWEKIECTESLVPMRKAYKGTFIVAGGYDRED

[0072] GNRALIEDRADLVAYGRLFISNPDLPKRFELNAPLNKYNRDTFYTSDPIVGYTDYPFLETMTLEHHHHHH。

[0073] The amino acid sequence of YersER is shown in SEQ ID No.4:

[0074] MKTAKLFSPLKVGALTLPNRVFMAPLTRLRSIEPGDIPTPLMAEYYRQRAS

[0075] AGLIITEATQISFQAKGYAGAPGLHTQEQLNAWKKITQAVHEEGGHIAVQLWH

[0076] VGRISHSSLQPGQQAPVAPSAIAADTRTTVRDENGAWVRVPCSTPRALETEEIP

[0077] GIINDFRQATANAREAGFDYIELHAAHGYLLHQFMSPASNQRTDQYGGSIENR

[0078] TRLTLEVVDATAAQWSAERIGIRISPLGPFNGLDNGEDQEEAALYLIDELNKR

[0079] HIAYLHISEPDWAGGKPYSEAFRDAVRARFKGVIIGAGAYTAEKAEELIEKGFI

[0080] DAVAFGRSYISNPDLVARLQQHAPLNEPDGETFYGGGAKGYTDYPTLKLAAALEHHHHHH。

[0081] The amino acid sequence of NostocER is shown in SEQ ID No.5:

[0082] MSDEAERQRGNNLYKNSPLLPVSISQVSTSQLRETEIMSTNINLFSSYQLGE

[0083] LELPNRIVMAPLTRQRAGEGNVPHQLNAIYYGQRASAGLIIAEATQVTPQGQG

[0084] YPHTPGIHSPEQVAGWKLVTDTVHQQGGRIFLQLWHVGRISHPDLQPDGGLP

[0085] VAPSAIAPKGEVLTYEGKKPYVTPRALDTSEIPAIVEQYRQGAANALAAGFDG

[0086] VEIHAANGYLIDQFLRDGTNQRTDEYGGAIENRARLLLEVTEAITSVWDSQR

[0087] VGVRLSPSGTFNDIRDSHPLETFGYVAQALNRFNLSYLHIFEAIDADIRHGGTV

[0088] VPTSHLRDRFTGTLIVNGGYTREKGDTVIANKAADLVAFGTLFISNPDLPERLEVNAPLNQADPTTFYGGGEKGYTDYPFLAVANKHHHHHH。

[0089] The amino acid sequence of NCR is shown in SEQ ID No.6:

[0090] MPSLFDPIRFGAFTAKNRIWMAPLTRGRATRDHVPTEIMAEYYAQRASAG

[0091] LIISEATGISQEGLGWPYAPGIWSDAQVEAWLPITQAVHDAGGLIFAQLWHMG

[0092] RMVPSNVSGMQPVAPSASQAPGLGHTYDGKKPYDVARALRLDEIPRLLDDY

[0093] EKAARHALKAGFDGVQIHAANGYLIDEFIRDSTNHRHDEYGGAVENRIRLLK

[0094] DVTERVIATIGKERTAVRLSPNGEIQGTVDSHPEQVFIPAAKMLSDLDIAFLGM

[0095] REGAVDGTFGKTDQPKLSPEIRKVFKPPLVLNQDYTFETAQAALDSGVADAISFGRPFIGNPDLPRRFFEKAPLTKDVIETWYTQTPKGYTDYPLLGDHHHHHHH.

[0096] The LED light source is a blue LED light source with a wavelength of 390-430nm; the reaction time is 12-24h; the co-solvent includes dimethyl sulfoxide, isopropanol, acetonitrile or N,N-dimethylformamide; the volume ratio of the co-solvent in the buffered salt solution is 1-10%.

[0097] In one embodiment of the present invention, the LED light source is a blue LED light source with a wavelength of 390-430nm; the reaction time is 12h, 16h, 20h or 24h; the co-solvent is dimethyl sulfoxide, isopropanol, acetonitrile or N,N-dimethylformamide; the volume ratio of the co-solvent in the buffered saline solution is 1%, 2%, 5%, 8% or 10%.

[0098] The (R)-N-acetyl-α-arylethylamine derivative specifically comprises the following steps:

[0099] (1) Add buffer solution, olefin reductase, reductase cofactor, glucose dehydrogenase (GDH), oxidized nicotinamide purine dinucleotide phosphate (NADP) to the reaction vessel in sequence. + ), D-glucose to obtain a mixed solution, then add the substrate enamide solution to obtain a reaction solution, and react at room temperature under nitrogen atmosphere and LED light for 12-24h;

[0100] (2) After the reaction is completed, a saturated sodium carbonate solution and ethyl acetate are added to the reaction container in sequence for extraction to obtain a (R)-N-acetyl-α-arylethylamine derivative, and then the reaction yield is analyzed by gas chromatography (internal standard curve method), and the enantiomeric selectivity is analyzed by high performance liquid chromatography (chiral chromatography column).

[0101] In one embodiment of the present invention, in step (1), the buffer salt is phosphate, tris(hydroxymethylaminomethane) hydrochloride, 3-(N-morpholinyl)propanesulfonate, hydroxyethylpiperazine ethanesulfonate or tris(hydroxymethylmethylglycine), and the concentration of the buffer salt solution is 25mmol / L, 50mmol / L, 100mmol / L or 200mmol / L, and the pH is 7.0, 8.0 or 9.0.

[0102] In one embodiment of the present invention, in step (1), the amount of the olefin reductase relative to the substrate is 0.5 mol%, 1.0 mol%, 2.0 mol% or 3 mol%; the olefin reductase cofactor is flavin mononucleotide sodium, and the amount of the olefin reductase cofactor relative to the substrate is 0, 0.5 mol%, 2 mol% or 3 mol%.

[0103] In one embodiment of the present invention, in step (1), in the reaction solution, the concentration of the glucose dehydrogenase solution is 1 U / mL, 5 U / mL, 10 U / mL or 20 U / mL; the amount of the oxidized nicotinamide purine dinucleotide phosphate solution relative to the substrate is 2 mol%, 5 mol%, 10 mol%, 15 mol% or 20 mol%; the equivalent of the D-glucose solution is 2 equivalents, 5 equivalents, 8 equivalents or 10 equivalents; in step (2), the volume ratio of the saturated sodium carbonate solution to ethyl acetate is 1:1, 1:2, 1:5, 1:8 or 1:10.

[0104] In one embodiment of the present invention, the substrate enamide is dissolved in DMSO solution to obtain a substrate-containing DMSO solution with a total volume of 32 μL and an enamide concentration of 0.25 mmol / mL; the volume ratio of the enamide-containing DMSO solution to the reaction solution is 2:100.

[0105] The technical solution of the present invention is further described below through specific embodiments.

[0106] Example 1

[0107] The preparation of (R)-N-(1-phenylethyl)acetamide, the reaction formula is as follows:

[0108]

[0109] The preparation method is as follows:

[0110] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G-Y375F enzyme solution (1 mol%), FMN-Na solution (0.5 mol%), GDH (glucose dehydrogenase) enzyme solution (5 U / mL), NADP + Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution fades, a mixed solution is obtained, and a DMSO (dimethyl sulfoxide) solution (0.008 mmol) of the substrate N-(1-phenylvinyl) acetamide is added, the total volume of the reaction solution is 1600 μL, and the total volume of the DMSO solution containing the substrate is 32 μL. Then, the mixture is placed under nitrogen protection and irradiated with a 390-430 nm blue light LED and stirred for 24 hours.

[0111] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial to extract and obtain (R)-N-(1-phenylethyl)acetamide.

[0112] The reaction yield was 78% by gas chromatography (internal standard curve method), and the product enantiomer ratio was 95:5 by chiral high performance liquid chromatography. The absolute configuration was determined to be R configuration by comparison with commercial enantiomer-pure compounds. The characterization data of the racemic standard are as follows:

[0113] 1 H NMR (400 MHz, CDCl 3 )δ7.36–7.24(m,5H),6.01(brs,1H),5.17–5.06(m,1H),1.96(s,3H),1.47(d,J=6.9Hz,3H).

[0114] 13 C NMR (100 MHz, CDCl 3 )δ169.2,143.2,128.7,127.4,126.2,48.8,23.4,21.7.

[0115] Example 2

[0116] The preparation of (R)-N-(1-phenylethyl)acetamide, the reaction formula is as follows:

[0117]

[0118] The preparation method is as follows:

[0119] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G-Y375F enzyme solution (0.5 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP + Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of the substrate N-(1-phenylvinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the reaction was stirred under 390-430 nm LED light under nitrogen protection for 24 hours.

[0120] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial to extract and obtain (R)-N-(1-phenylethyl)acetamide.

[0121] The reaction yield was 65% as analyzed by gas chromatography (internal standard curve method), the enantiomeric ratio of the product was 95:5 as analyzed by chiral high performance liquid chromatography, and the absolute configuration was determined to be R configuration by comparison with a commercial enantiomer-pure compound.

[0122] Example 3

[0123] The preparation of (R)-N-(1-phenylethyl)acetamide, the reaction formula is as follows:

[0124]

[0125] The preparation method is as follows:

[0126] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G-Y375F enzyme solution (1 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP + Solution (2 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of substrate N-(1-phenylvinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the mixture was placed under nitrogen protection and irradiated with a 390-430 nm blue LED and stirred for 24 h.

[0127] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0128] The reaction yield was 63% as analyzed by gas chromatography (internal standard curve method), the enantiomeric ratio of the product was 95:5 as analyzed by chiral high performance liquid chromatography, and the absolute configuration was determined to be R configuration by comparison with a commercial enantiomer-pure compound.

[0129] Example 4

[0130] The preparation of (R)-N-methyl-N-(1-phenylethyl)acetamide, the reaction formula is as follows:

[0131]

[0132] The preparation method is as follows:

[0133] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1 enzyme solution (1 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP +Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of substrate N-methyl-N-(1-phenylvinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the reaction was stirred for 24 hours under nitrogen protection and irradiated with 390-430 nm LED light.

[0134] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0135] The reaction yield was 77% using gas chromatography (internal standard curve method), and the product enantiomeric ratio was 97:3 using chiral high performance liquid chromatography. The characterization data of the racemic standard are as follows:

[0136] 1 H NMR (400 MHz, CDCl 3 )δ7.39–7.24(m,5H),6.07(q,J=7.1Hz,0.67H,major),5.10(q,J=7.0Hz,0.33H,minor),2.68(s,1H,minor),2.66( s,2H,major),2.25(s,1H,minor),2.14(s,2H,major),1.61(d,J=7.0Hz,1H,minor),1.48(d,J=7.1Hz,2H,major).

[0137] 13 C NMR (100 MHz, CDCl 3 )major rotamer: δ170.7,140.6,128.4,127.3,127.2,50.1,30.2,22.2,15.5; minor rotamer: δ170.7,140.2,128.8,127.6,126.4,55.7,27.8,21.7,17.6.

[0138] Example 5

[0139] The preparation of (R)-N-(1,2,3,4-tetrahydronaphthalene-1-yl)acetamide, the reaction formula is as follows:

[0140]

[0141] The preparation method is as follows:

[0142] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G enzyme solution (2 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP + Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, the substrate N-(3,4-dihydronaphthalen-1-yl)acetamide DMSO solution (0.008 mmol) was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, under nitrogen protection, the reaction was stirred under 390-430 nm blue LED light for 24 hours.

[0143] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0144] The reaction yield was 80% using gas chromatography (internal standard curve method), and the product enantiomeric ratio was 93:7 using chiral high performance liquid chromatography. The characterization data of the racemic standard are as follows: 1 H NMR (400 MHz, CDCl 3 )δ7.30–7.22(m,1H),7.22–7.13(m,2H),7.17–7.06(m,1H),5.78(brs,1H),5.21 –5.13(m,1H),2.87–2.69(m,2H),2.07–2.02(m,1H),2.01(s,3H),1.87–1.753H).

[0145] 13 C NMR (100 MHz, CDCl 3 )δ169.3,137.6,136.7,129.2,128.7,127.3,126.3,47.5,30.1,29.2,19.9.

[0146] Example 6

[0147] Preparation of (R)-N-methyl-N-(1-(4-tert-butylphenyl)ethyl)acetamide, the reaction formula is as follows:

[0148]

[0149] The preparation method is as follows:

[0150] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1 enzyme solution (2 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP+ Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of the substrate N-methyl-N-(1-(4-tert-butylphenyl)vinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the reaction was stirred for 24 hours under nitrogen protection under 390-430 nm blue LED light.

[0151] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0152] The reaction yield was 60% by gas chromatography (internal standard curve method), and the product enantiomeric ratio was 98:2 by chiral high performance liquid chromatography. The characterization data of the racemic standard are as follows:

[0153] 1 H NMR (400 MHz, CDCl 3 )δ7.41–7.31(m,2H),7.23–7.13(m,2H),6.03(q,J=7.1Hz,0.67H,major),5.07(q,J=6.9Hz,0.33H,minor),2.68(s,1H,minor),2.66(s,2H,ma jor),2.24(s,minor),2.13(s,2H,major),1.59(d,J=6.9Hz,1H,minor),1.46(d,J=7.1Hz,2H,major),1.32(s,3H,minor),1.31(s,6H,major).

[0154] 13 C NMR (100 MHz, CDCl 3 )major rotamer: δ170.6,150.1,137.5,127.0,125.3,49.9,34.4,31.3,30.3,22.3,15.6; minor rotamer: δ170.6,150.6,137.1,126.1,125.6,55.5,34.5,31.3,27.8,21.7,17.6.

[0155] Example 7

[0156] Preparation of Cinacalcet synthetic intermediate (R)-N-(1-(α-naphthyl)ethyl)acetamide, the reaction formula is as follows:

[0157]

[0158] The preparation method is as follows:

[0159] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1 enzyme solution (2 mol%), FMN-Na solution (1 mol%), GDH enzyme solution (5 U / mL), NADP + Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of the substrate N-(1-(α-naphthyl)vinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the reaction was stirred for 24 hours under nitrogen protection and irradiated with a 390-430 nm blue LED.

[0160] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0161] The reaction yield was 72% using gas chromatography (internal standard curve method), and the product enantiomeric ratio was 95:5 using chiral high performance liquid chromatography. The characterization data of the racemic standard are as follows:

[0162] 1 H NMR (400 MHz, CDCl 3 )δ8.13–8.06(m,1H),7.89–7.82(m,1H),7.82–7.75(m,1H),7.59–7.40(m, 4H), 5.97–5.85 (m, 1H), 5.83 (brs, 1H), 1.94 (s, 3H), 1.65 (d, J = 6.6Hz, 3H).

[0163] 13 C NMR (100 MHz, CDCl 3 )δ169.0,138.3,133.9,131.1,128.8,128.4,126.6,125.9,125.2,123.5,122.6,44.7,23.3,20.7.

[0164] Example 8

[0165] Preparation of (R)-Conulothiazole A total synthetic intermediate (R)-N-(1-(thiazol-2-yl)ethyl)acetamide, the reaction formula is as follows:

[0166]

[0167] The preparation method is as follows:

[0168] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G-Y375F enzyme solution (2 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP + Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.008 mmol) of the substrate N-(1-(thiazol-2-yl)vinyl)acetamide was added, the total volume of the reaction solution was 1600 μL, and the total volume of DMSO was 32 μL. Then, the reaction was stirred for 24 hours under nitrogen protection under 390-430 nm blue LED light.

[0169] After the reaction was completed, 200 μL of saturated sodium carbonate solution and 1600 μL of ethyl acetate were added to the reaction vial for extraction.

[0170] The reaction yield was 84% ​​using gas chromatography (internal standard curve method), and the product enantiomeric ratio was 89:11 using chiral high performance liquid chromatography. The characterization data of the racemic standard are as follows:

[0171] 1 H NMR (400 MHz, CDCl 3 )δ7.70(d,J=3.3Hz,1H),7.27(d,J=3.2Hz,1H),6.50(brs,1H),5.49–5.38(m,1H),2.04(s,3H),1.61(d,J=6.9Hz,3H).

[0172] 13 C NMR (100 MHz, CDCl 3 )δ172.1,169.4,142.2,119.0,47.0,23.3,22.0.

[0173] Example 9

[0174] The 0.1 mmol preparation of (R)-N-(1-(Benzofuran-2-yl)ethyl)acetamide is as follows:

[0175]

[0176] The preparation method is as follows:

[0177] First, potassium phosphate buffer (50 mmol / L, pH 8.0), OYE1-F296G enzyme solution (1 mol%), FMN-Na solution (0.5 mol%), GDH enzyme solution (5 U / mL), NADP +Solution (10 mol%) and glucose solution (5 equivalents), after the yellow color of the solution faded, a DMSO solution (0.1 mmol) of the substrate N-(1-(benzofuran-2-yl)vinyl)acetamide was added, the total volume of the reaction solution was 20 mL, and the total volume of DMSO was 400 μL. Then, the reaction was stirred for 24 hours under nitrogen protection under 390-430 nm blue LED light.

[0178] After the reaction, 2.5 mL of saturated sodium carbonate solution and 20 mL of ethyl acetate were added to the sealed tube for extraction. The target product was purified and separated using silica gel column chromatography with a yield of 60%. The enantiomeric ratio of the product was 96.5:3.5 using chiral high performance liquid chromatography. The product characterization data are as follows:

[0179] 1 H NMR (400 MHz, CDCl 3 )δ7.54–7.47(m,1H),7.46–7.40(m,1H),7.32–7.14(m,2H),6.57–6.52(m, 1H), 5.98 (brs, 1H), 5.41–5.27 (m, 1H), 2.01 (s, 3H), 1.56 (d, J = 7.0Hz, 3H).

[0180] 13 C NMR (100 MHz, CDCl 3 )δ169.2,158.0,154.7,128.1,124.1,122.8,121.0,111.1,102.4,43.3,23.3,19.7.

[0181] The above is only a preferred embodiment of the present invention, and the present invention is not limited to the above embodiments. It is understood that other improvements and changes directly derived or associated by those skilled in the art without departing from the spirit and concept of the present invention should be considered to be included in the protection scope of the present invention.

Claims

1. A method for preparing (R)-N-acetyl-α-arylethylamine derivatives by photoenzyme-catalyzed asymmetric reduction, characterized in that: The method comprises the following steps: the substrate enamide is placed in a buffered salt solution containing a cosolvent, an olefin reductase is used as a biocatalyst, and in the presence of an olefin reductase cofactor and a cofactor circulation system, the reaction is irradiated with an LED light source in a nitrogen atmosphere, and the reaction is stirred to obtain the product. The general reaction formula is as follows: in: Ar includes phenyl, C1-C6 substituted phenyl, naphthyl or heterocyclic substituents; R 1 Selected from acetyl, tert-butyloxycarbonyl, trifluoroacetyl, benzoyl; R 2 is selected from a hydrogen atom, an alkyl group or an allyl group; R 3 is selected from a hydrogen atom or an alkyl group.

2. The method according to claim 1, characterized in that The phenyl substituent is selected from a halogen atom, a methoxy group, a methylthio group, a methyl group, a tert-butyl group, a trifluoromethyl group, an ester group or a cyano group.

3. The method according to claim 1, characterized in that: The heterocyclic substituent is selected from thiazole, thiophene, furan, benzofuran, benzothiophene or pyridine.

4. The method according to claim 1, characterized in that: The alkene reductase includes OYE1, OYE1 mutant, GluER, OPR1, YersER, NostocER or NCR; the alkene reductase OYE1 is obtained by expressing in E.coli BL21 (DE3) and purifying the protein.

5. The method according to claim 1, characterized in that The olefin reductase OYE1 mutant is a mutant having at least one of the following mutations compared with SEQ ID No. 1: The phenylalanine at position 296 is substituted with glycine, alanine, or leucine; The tyrosine at position 196 is substituted with phenylalanine; The tyrosine at position 375 was substituted with phenylalanine; The phenylalanine at position 250 is substituted with alanine, leucine, or glycine; Asparagine at position 194 was substituted with alanine; The phenylalanine at position 374 was substituted with alanine.

6. The method according to claim 1, characterized in that The LED light source is a blue LED light source with a wavelength of 390-430nm; the reaction time is 12-24h; the co-solvent includes dimethyl sulfoxide, isopropanol, acetonitrile or N,N-dimethylformamide; the volume fraction of the co-solvent in the buffered salt solution is 1-10%.

7. The method according to claim 1, characterized in that The method specifically comprises the following steps: (1) adding a buffered saline solution, an olefin reductase, a reductase cofactor, glucose dehydrogenase, oxidized nicotinamide purine dinucleotide phosphate, and D-glucose to a reaction container in sequence to obtain a mixed solution, then adding a substrate olefin amide to obtain a reaction solution, and reacting at room temperature under a nitrogen atmosphere and LED light for 12-24 hours; (2) After the reaction is completed, saturated sodium carbonate solution and ethyl acetate are added to the reaction container in sequence for extraction to obtain a (R)-N-acetyl-α-arylethylamine derivative.

8. The method according to claim 7, characterized in that In step (1), the buffer salt includes phosphate, tris(hydroxymethylaminomethane) hydrochloride, 3-(N-morpholinyl)propanesulfonate, hydroxyethylpiperazine ethanesulfonate or tris(hydroxymethylmethylglycine), and the concentration of the buffer salt solution is 25-200 mmol / L, and the pH is 7.0-9.

0.

9. The method according to claim 7, characterized in that: In step (1), the amount of olefin reductase relative to the substrate is 0.5-3 mol%; the olefin reductase cofactor is sodium flavin mononucleotide, and the amount of olefin reductase cofactor relative to the substrate is 0-3 mol%.

10. The method according to claim 7, characterized in that In step (1), the concentration of glucose dehydrogenase in the reaction solution is 1-20 U / mL; the amount of oxidized nicotinamide purine dinucleotide phosphate relative to the substrate is 2-20 mol%; the equivalent of D-glucose in the reaction solution is 2-10 equivalents; in step (2), the volume ratio of the saturated sodium carbonate solution to ethyl acetate is 1:1-10.